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Public concern on issues such as animal
welfare or the scientific validity and
clinical value of animal research is grow-
ing, resulting in increasing regulatory
demands for animal research. Abiding to
the most stringent animal welfare stan-
dards, while having scientific objectives as
the main priority, is often challenging.
To do so, endpoints of studies involving
severe, progressive diseases need to be
established considering how early in the
disease process the scientific objectives can
be achieved. We present here experimen-
tal studies of tuberculosis (TB) in mice
as a case study for an analysis of present
practice and a discussion of how more
refined science-based endpoints can be
developed. A considerable proportion of
studies in this field involve lethal stages,
and the establishment of earlier, reliable
indicators of disease severity will have a
significant impact on animal welfare.
While there is an increasing interest from
scientists and industry in moving research
in this direction, this is still far from being
reflected in actual practice. We argue that
a major limiting factor is the absence of
data on biomarkers that can be used as
indicators of disease severity. We discuss
the possibility of complementing the
widely used weight loss with other relevant
biomarkers and the need for validation of
these parameters as endpoints. Promotion
of ethical guidelines needs to be coupled
with systematic research in order to
develop humane endpoints beyond the
present euthanasia of moribund animals.
Such research, as we propose here for
chronic infection, can show the way for
the development and promotion of welfare
policies in other fields of research.
Research on chronic infection relies
heavily on the use of animals, as only the
integral animal body can model the full
aspect of an infection. That animals are
generally made to develop a disease in
infection studies exacerbates the tension
between human benefit and animal well-
being, which characterizes all biomedical
research with animals. Scientists typically
justify animal research with reference to
potential human benefits, but if accepting
the assumption that human benefits can
offset animal suffering, it still needs to be
argued that the same benefits could not be
achieved with less negative effects on
animal welfare. Reducing the animal
welfare problems associated with research
(‘‘refinement’’ [1]) is therefore crucial in
order to render animal-based research less
of an ethical problem and to assure public
trust in research.
Studies that are designed to measure
time of death or survival percentages
present a particularly challenging situation
in which at least some of the animals are
made to die from the disease. These
studies are frequent in experimental re-
search on severe infections. The scientific
community, industry, and regulatory au-
thorities have responded to the ethical
concerns over studies in which animals die
from severe disease by developing new
policies and guidelines for the implemen-
tation of humane endpoints as a key
refinement measure (e.g., [2–4]). The most
widely used definition considers a humane
endpoint to be the earliest indicator in an
animal experiment of severe pain, severe
distress, suffering, or impending death [5],
underlining that ideally such indicators
should be identified before the onset of the
most severe effects.
Euthanizing animals, rather than await-
ing their ‘‘spontaneous’’ death, is impor-
tant to avoid unnecessary suffering in
studies in which data on survival is thought
to be required for scientific or legal
reasons. However, several questions re-
main open regarding how humane end-
points are to be applied to address real
animal welfare problems. We used TB
experiments in mice as a case study to
highlight the potential to establish bio-
markers of disease progress that can
replace survival time as a measure of
disease severity.
Humane Endpoints Applied to
Murine TB Experiments—State
of the Arts
To illustrate the state of the art in the
implementation of humane endpoints, we
present data from a systematic review of
articles published on murine TB in 2009.
Papers were selected by performing an
advanced search on the ISI Web of
Science database (search performed in
June 2011, using the previous 4.1 version,
accessible at http://webofknowledgev4.com)
with the terms ‘‘TS= ((mouse OR mice)
SAME tuberculosis) AND PY= (2009)’’
and refined to exclude reviews, proceed-
ings, articles in languages other than
English, in vitro studies, and studies on
other animal species and/or with other
infectious agents than Mycobacterium tuber-
culosis, which resulted in a total of 80
papers reviewed. The severity of disease
of the animals used in each study was
analyzed in terms of the disease stage
animals were allowed to reach, the
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carrying out of invasive procedures and
the implementation of relevant refine-
ment measures, and humane endpoints in
particular. All studies in which animals
were allowed to die spontaneously or to
reach a moribund state were considered
among the highest level of severity. Also,
depending on whether studies were termi-
nated before animals reached advanced
stages of disease (which would rapidly
progress towards spontaneous death if no
other endpoints were applied) or not, these
were classified as ‘‘lethal’’ or ‘‘non-lethal’’,
respectively. Lethal studies comprised those
conducted in very susceptible strains as well
as in more resistant mouse strains in which
disease was allowed to progress to very
advanced stages. Nearly half (47%) of the
studies fit the lethal category, of which
66% were classified within the highest
severity level. Although 26% of lethal
studies explicitly reported having applied
humane endpoints to avoid spontaneous
death, in most of these studies (eight out
of ten) humane endpoints were applied
when animals were moribund and se-
verely cachectic or when other animals
in the same group began to die. Thus,
most such endpoints consisted of merely
replacing spontaneous death with eutha-
nasia of moribund animals and may
therefore fail to have a significant impact
on the degree of poor animal well-being.
Of the 25 studies considered within the
highest severity, 24 had reported some
sort of regulatory compliance, of which
17 explicitly stated that the study had
been ethically approved.
Are Near-Death Endpoints
Really Humane?
The attention to humane endpoints is
reflected in an increase in their implemen-
tation. This is clearly visible when review-
ing research on murine TB: while the use
of humane endpoints is reported in 26% of
the terminal infection studies published in
2009, the same figure for 1999 is 15%
(three of 20 papers reporting studies on
lethal infections). However, a careful
analysis reveals a significant limitation of
humane endpoints as they are often
presently applied. In fact, from both
scientific and ethical perspectives, it is
questionable if euthanasia of moribund
animals is the most effective measure to
prevent excessive animal suffering. It is
admittedly difficult to estimate how much
awareness of aversive sensations an indi-
vidual retains in such a debilitated,
unresponsive, and seemingly comatose
state as the moribund animal is in [6].
But considering that the moribund state
constitutes a terminal stage of a progres-
sively distressing disease, the main animal
welfare problem consists in the unrelieved
suffering that precedes it. Furthermore,
there is also the risk that researchers (as
well as journal editors and animal ethics /
animal care and use committees) may see
euthanasia of moribund animals as a
sufficient measure to guarantee the ‘‘eth-
icality’’ of their studies, thus hindering the
pursuit for more welfare-relevant end-
points. An additional scientific concern
pertains to the definition of the ‘‘moribund
state’’ in itself; it is seldom defined in the
material and methods section of the
published articles. Therefore, it is unclear
which clinical signs are used as indicators
of imminent or pending death, and how
soon before the estimated time of death
they are detectable.
The Potential for Scientific
Refinement of Endpoints in
Studies on Chronic Infection—
Murine TB as a Case Study
We focus here on mice models for TB as
a case study to discuss the potential for
refining endpoints from both animal
welfare and scientific viewpoints. TB is
representative of chronic infection re-
search in which, typically, adult animals
are studied in experiments that last several
weeks. The long duration means a greater
potential—as well as a stronger animal
welfare reason—for developing more re-
fined early endpoints than in infections of
a more acute nature. Mice experimentally
infected with M. tuberculosis develop TB
as a progressive disease. Although mouse
strains vary in their susceptibility to
infection [7], all mice eventually succumb
to experimental TB [8,9] and die before
their natural average life-span if no
measures are undertaken to treat them.
Even the more TB-resistant C57BL/6
mice have a median survival time of fewer
than 300 days [8], while uninfected
animals live over 800 days [10], irrespec-
tive of the number of viable bacteria with
which they are infected.
Time to death, when animals are found
dead in the cage, is a frequently used
outcome measure in experimental TB
studies. Of studies published in 2009,
31% (25 out of 80) used death (18 out of
25) or the moribund stage (7 out of 25) as
endpoints. Of notice and certainly as a
consequence of awareness of animal
welfare issues, an increasing number of
studies are defining death as the time
point when moribund animals are eutha-
nized, rather than the time when they are
found dead. This approach improves
scientific accuracy both in that the exact
time of death is known and in that
biological samples can be collected im-
mediately post-mortem. The informative
value of time to death for understanding
disease physiopathology is, however, lim-
ited by the fact that the actual cause of
death may vary between animals: mice
infected with M. tuberculosis may die from
different lung pathologies in response to
experimental infection [8,11–13], as well
as from causes only indirectly related to
infection such as sepsis [14], hunger, or
dehydration [15].
While euthanasia of moribund animals
is an improvement compared to using
death as an endpoint, as we have argued
above, it is still a rather inefficient measure
to safeguard animal welfare. Nevertheless,
in the absence of validated predictors of
death, this may presently be the best
researchers can do if they need to establish
whether animals reached a state from
which they will deteriorate and die or
might still recover. Identification of the
turning point towards terminal disease,
with greater understanding of the under-
lying host and pathogen factors leading to
this stage, may provide endpoint measures
that reliably reflect disease progression.
Research on early predictors of a terminal
disease stage (sometimes termed ‘‘surro-
gate endpoints’’ [16]), at times in which
scientifically relevant data can be obtained
before animals reach pronounced levels of
distress, should therefore be encouraged.
Humane endpoint protocols are usually
based on a combination of clinical signs;
however, objectively and numerically
measurable parameters are sometimes
included [17]. Amidst these, percentage
of body weight loss is the most commonly
used as a cut-off parameter for euthanasia
in experimental TB studies in mice, since
it can be used as an objective measure of
infection-related morbidity in this animal
model (e.g., [18]). While non-infected mice
tend to maintain or gain body weight,
infected and untreated mice start to lose
weight on account of active disease, in an
irreversible and fairly linear manner
[19,20–23]. A consistent correlation be-
tween weight loss and survival has been
reported specifically for backcrossed ani-
mals derived from A/Sn and I/St mice
[23–25], which led Nikonenko and co-
workers [25] to propose that drug efficacy
can be evaluated through the systematic
assessment of body weight changes in
rapidly progressive TB in C3H mice, an
immunocompetent but TB-susceptible
strain.
Although this parameter is in itself
quantitative and objectively measurable,
PLoS Pathogens | www.plospathogens.org 2 January 2012 | Volume 8 | Issue 1 | e1002399
the definition of the upper boundary
values for euthanasia is potentially subjec-
tive, unless previously validated against
data on disease progress and survival.
Threshold weight losses vary considerably
across studies, ranging from 15% of pre-
infection weight [26] or of the average
weight of control mice [27] to more severe
20% [28], 25% [29], or even 30% weight
loss [30], with no scientific justification for
choosing different cut-off points in differ-
ent studies.
Systematic studies, in which data on
biomarkers are collected repeatedly as the
disease progresses and biomarker data is
correlated with survival, are essential to
develop new potential predictors of
death/survival. Such studies need to be
carried out specifically for distinct combi-
nations of mouse and bacterial strains,
with the aim of detecting selected bio-
markers that indicate the point of no
return after which animals do not recover.
In addition to body weight, non-transient
hypothermia has been suggested as a
potentially useful predictor of death in
some models of infection [31–36]. Hypo-
thermia typically settles when disease
reaches a near fatal stage and body
temperature (which can be measured
without handling stress by either infrared
thermometers [35] or telemetric monitor-
ing [36]) may constitute an important
refinement of current moribund end-
points, particularly if scored with other
clinical parameters [16]. A non-invasive
method for the assessment of blood
oxygen saturation in a murine model of
viral pulmonary disease has also been
shown to be a more reliable indicator of
lung pathology and predictor of disease
outcome than body weight loss [37]. This
indicator of lung function has the poten-
tial to be used as a measure of morbidity
in other pulmonary diseases if this can be
validated in further research. Animals
dying from distinct prolonged chronic
infections have been shown to present
other pathophysiological alterations that
could be carefully studied as potential
blood biomarkers of approaching death.
These include anaemia and/or erythro-
poiesis and the metabolic perturbations in
the glycolytic enzyme pathway with
consequent altered blood glucose homeo-
stasis, parameters that might be easily
analyzed in blood samples and have been
shown to correlate with the degree of
disease severity [38,39]. Biomarkers relat-
ed to the immune response to infection
are also described as potential indicators,
reflecting the animals’ capacity to control
the infection. In addition to the most
widely studied cytokines associated with
susceptibility/resistance to TB, like IFN-
c, TNF, IL-1, and IL-10 analyzed indi-
vidually or in combinations [40–42],
others have been suggested. A set of
transcriptional biomarkers was recently
shown to serve as diagnostic and prog-
nostic tools, by the identification of a TB-
specific 86-gene transcriptome signature
in whole-blood samples, with the tran-
scriptional signature being shown to
correlate with extent of disease in patients
with active TB and to also reflect changes
at the site of disease [43]. However, while
potentially clinically interesting, its mea-
surement might be cumbersome unless a
smaller number of transcripts proves to be
still valid as molecular signature.
Meeting Ethical Standards by a
Science-Based Approach to
Endpoints
It is praiseworthy that researchers,
institutions, the public, and the authorities
are all more aware of the need to establish
ethical guidelines and rules in animal
research to minimize distress. With that
purpose, euthanasia is nowadays common-
ly established in most animal facilities
when animals reach distress levels consid-
ered to be beyond an ‘‘acceptable’’
threshold [44]. There are, however, sev-
eral problems with such a practice being
imposed on research from external enti-
ties. First, the level found acceptable is
bound to be somewhat arbitrary, depend-
ing on factors such as the research
institution guidelines and the opinions of
the appointed veterinarian, animal welfare
officer, and members of the ethics com-
mittee. Second, from a scientific view-
point, it is crucial to make sure that
experimental objectives are not compro-
mised by loss of experimental data due to
unexpected deaths or compulsory eutha-
nasia. Therefore, the establishment of
earlier endpoints should ideally be cen-
tered on the earliest time point allowing
the collection of adequate scientific infor-
mation and valuable biological material,
rather than on welfare-centered criteria.
As discussed above, in many cases
additional research will be necessary to
establish the correspondence of early
clinical signs and final disease outcome.
This calls for a new type of refinement
research, in which measures to reduce
animal welfare problems are developed
specifically for the various fields of
research and in close collaboration be-
tween laboratory animal specialists and
researchers using animal models. Some
such initiatives have emerged on the
national level (e.g., National Centre for
the 3Rs in the United Kingdom), but
major international funding is unfortu-
nately still limited to either the actual
biomedical research itself or alternative
methods to replace animal experiments,
thus excluding studies on how to refine
actual animal use.
Surrogate endpoints in the true sense
constitute a crucial refinement of studies
where a reliable measure of lethality is
assumed to be necessary, in particular
when these studies are long-term. We
emphasize, however, the collection of
informative data in less severe phases as
the ideal approach for basic and applied
research, allowing for a science-based,
rather than welfare-centered justification
for the termination of such experiments.
With respect to interventional euthana-
sia, although presently necessary to avoid
further suffering of animals reaching
unacceptably severe pain or other distress,
it must be emphasized that this interven-
tion ought to be more of an exception than
the rule, and that studies should be
planned so that such interventions are
unnecessary.
Conclusion
Animal research is valuable for identi-
fying mechanisms of disease and novel
therapies. The increased awareness of the
ethical issues pertaining to animal exper-
imentation requires that relevant scientific
information and biological materials are
obtained as early as possible, avoiding
that animals have to reach severe stages
of disease. In research on progressive
diseases, it is pertinent to identify early
surrogate endpoints of death as well as
reliable biomarkers of disease progression.
Changes in body weight and temperature,
along with biomarkers easily measured in
blood samples, should be carefully inves-
tigated as potential early predictors of
death/survival. A science-driven ap-
proach for the termination of animal
studies may not only prevent unnecessary
and avoidable suffering, but also contrib-
ute to optimizing financial and human
resources, enhancing the scientific output
and speeding up the scientific process.
The real humane endpoint challenge is to
extend this approach into situations
where presently the scientific outcome
measure requires that animals reach more
severe stages. While acknowledging cur-
rent efforts by funding bodies and char-
ities, regulators, industry, and academia
in promoting and developing new stan-
dards for animal welfare, we stress that
further collaborative research as well as
funding for such research is essential to
PLoS Pathogens | www.plospathogens.org 3 January 2012 | Volume 8 | Issue 1 | e1002399
achieve more meaningful refinement of
studies of chronic infections.
Protein Accession Numbers/IDs
N Ifng interferon gamma [Mus musculus];
Gene ID: 15978; Protein ID: NP_
032363
N Tnf tumor necrosis factor [Mus muscu-
lus]; Gene ID: 21926; Protein ID: NP_
038721
N Il1b interleukin 1 beta [Mus musculus];
Gene ID: 16176; Protein ID: NP_
032387
N Il10 interleukin 10 [Mus musculus];
Gene ID: 16153; Protein ID: NP_
034678
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